Colorectal Cancer
The study’s primary end point was objective response rate determined through blinded independent central review.
Immunoscore also showed prognostic benefit in DNA mismatch repair proficient disease.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
In patients with stage 4 colon cancer and unresectable metastases, PTR before chemotherapy was not related to increased OS.
Dr. Kasi showcases NEST-1, a look at adverse events and downstaging effects from neoadjuvant bot/bal in pMMR/MSS CRC.
Dr. Kasi breaks down BESPOKE CRC, a tumor-informed ctDNA assay to inform adjuvant chemo treatment decisions in stage 2/3 CRC.
Previous studies have demonstrated that patients with rectal cancer and enlarged LLNs experience a higher risk of LLR.
Recent studies have demonstrated the efficacy of blood-based and stool DNA tests as CRC screening options.
Dr. Christopher Lieu gives an overview of the BESPOKE trial and the GALAXY arm of CIRCULATE-Japan, as well as NETTER-2.
Dr. Pant discusses the relationship between T cell response magnitude and tumor biomarker reduction.
A2B530 is the first autologous logic-gated cell therapy developed using A2 Biopharmaceutical’s Tmod platform.
Dr. Eng discusses how fruquintinib differs from other VEGFR inhibitors.
Advertisement
Expert Interviews on GI Oncology
Advertisement
